Detalles de la búsqueda
1.
Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.
Haematologica
; 105(1): e22-e25, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31048356
2.
Radiological, pathological and surgical outcomes after neoadjuvant endocrine treatment in patients with ER-positive/HER2-negative breast cancer with a clinical high risk and a low-risk 70-gene signature.
Breast
; 75: 103726, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38599047
3.
Daratumumab monotherapy in refractory warm autoimmune hemolytic anemia and cold agglutinin disease.
Blood Adv
; 8(11): 2622-2634, 2024 Jun 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-38507742
4.
T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia.
Blood Adv
; 7(21): 6540-6552, 2023 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-37552122
5.
Ibrutinib plus Obinutuzumab as Frontline Therapy for Chronic Lymphocytic Leukemia Is Associated with a Lower Rate of Infusion-Related Reactions and with Sustained Remissions after Ibrutinib Discontinuation: A Single-Arm, Open-Label, Phase 1b/2 Clinical Trial NCT0231576.
Adv Hematol
; 2022: 4450824, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35103064
6.
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
Blood Adv
; 5(3): 913-925, 2021 02 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33560402
Resultados
1 -
6
de 6
1
Próxima >
>>